source
- Axiom's stem cell therapy shows zero mortality in phase-1 trial for newborn brain injuriesAxiom Biosciences reported that its mesenchymal stem cell (MSC) therapy achieved a 0% mortality rate over two years in a phase‑1 study of newborns with severe brain injuries. The nine‑patient trial…
- CVS Caremark settles FTC antitrust case, agreeing to favor lowest-cost insulin on formulariesCVS Caremark announced a settlement with the Federal Trade Commission that resolves the agency’s antitrust lawsuit alleging the PBM favored higher-priced insulin versions. Under the agreement, Car…